These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 32487753)

  • 1. Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
    Grimsey EM; Fais C; Marshall RL; Ricci V; Ciusa ML; Stone JW; Ivens A; Malloci G; Ruggerone P; Vargiu AV; Piddock LJV
    mBio; 2020 Jun; 11(3):. PubMed ID: 32487753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics Reveal Potential Natural Substrates of AcrB in Escherichia coli and Salmonella enterica Serovar Typhimurium.
    Wang-Kan X; Rodríguez-Blanco G; Southam AD; Winder CL; Dunn WB; Ivens A; Piddock LJV
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity.
    Blair JM; Bavro VN; Ricci V; Modi N; Cacciotto P; Kleinekathӧfer U; Ruggerone P; Vargiu AV; Baylay AJ; Smith HE; Brandon Y; Galloway D; Piddock LJ
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3511-6. PubMed ID: 25737552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
    Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
    Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of AcrB Efflux Function Confers Loss of Virulence on
    Wang-Kan X; Blair JMA; Chirullo B; Betts J; La Ragione RM; Ivens A; Ricci V; Opperman TJ; Piddock LJV
    mBio; 2017 Jul; 8(4):. PubMed ID: 28720734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors.
    Vargiu AV; Ruggerone P; Opperman TJ; Nguyen ST; Nikaido H
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6224-34. PubMed ID: 25114133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
    Mowla R; Wang Y; Ma S; Venter H
    Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
    Bailey AM; Paulsen IT; Piddock LJ
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3604-11. PubMed ID: 18694955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops.
    Elkins CA; Nikaido H
    J Bacteriol; 2002 Dec; 184(23):6490-8. PubMed ID: 12426336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Multidrug Efflux Inhibitors for Gram-Negative Bacteria.
    Marshall RL; Lloyd GS; Lawler AJ; Element SJ; Kaur J; Ciusa ML; Ricci V; Tschumi A; Kühne H; Alderwick LJ; Piddock LJV
    mBio; 2020 Jul; 11(4):. PubMed ID: 32665275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.
    Schuster S; Vavra M; Wirth DAN; Kern WV
    Microbiol Spectr; 2024 Feb; 12(2):e0304523. PubMed ID: 38170977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation.
    Aparna V; Dineshkumar K; Mohanalakshmi N; Velmurugan D; Hopper W
    PLoS One; 2014; 9(7):e101840. PubMed ID: 25025665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors.
    Schuster S; Kohler S; Buck A; Dambacher C; König A; Bohnert JA; Kern WV
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6870-8. PubMed ID: 25182653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
    Wang Y; Mowla R; Guo L; Ogunniyi AD; Rahman T; De Barros Lopes MA; Ma S; Venter H
    Bioorg Med Chem Lett; 2017 Feb; 27(4):733-739. PubMed ID: 28129976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2019 Garrod Lecture: MDR efflux in Gram-negative bacteria-how understanding resistance led to a new tool for drug discovery.
    Piddock LJV
    J Antimicrob Chemother; 2019 Nov; 74(11):3128-3134. PubMed ID: 31626705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of RamA, Which Regulates Production of the Multidrug Resistance Efflux Pump AcrAB-TolC, Increases Mutation Rate and Influences Drug Resistance Phenotype.
    Grimsey EM; Weston N; Ricci V; Stone JW; Piddock LJV
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps.
    Plé C; Tam HK; Vieira Da Cruz A; Compagne N; Jiménez-Castellanos JC; Müller RT; Pradel E; Foong WE; Malloci G; Ballée A; Kirchner MA; Moshfegh P; Herledan A; Herrmann A; Deprez B; Willand N; Vargiu AV; Pos KM; Flipo M; Hartkoorn RC
    Nat Commun; 2022 Jan; 13(1):115. PubMed ID: 35013254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Interactions of Carbapenem Antibiotics with the Multidrug Efflux Transporter AcrB of
    Atzori A; Malloci G; Cardamone F; Bosin A; Vargiu AV; Ruggerone P
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.
    Soparkar K; Kinana AD; Weeks JW; Morrison KD; Nikaido H; Misra R
    J Bacteriol; 2015 Oct; 197(20):3255-64. PubMed ID: 26240069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence, loss-of-function, or inhibition of Escherichia coli AcrB does not increase expression of other efflux pump genes supporting the discovery of AcrB inhibitors as antibiotic adjuvants.
    Ciusa ML; Marshall RL; Ricci V; Stone JW; Piddock LJV
    J Antimicrob Chemother; 2022 Feb; 77(3):633-640. PubMed ID: 34897478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.